Navigation Links
Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Date:1/9/2008

ng a child. In addition, women treated with Vidaza should not nurse.

About Pharmion

Pharmion is a leading global oncology company uniquely focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

About MethylGene

MethylGene Inc. (TSX: MYG) is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase 2 monotherapy and Phase 1 and Phase 2 combination trials with Vidaza(R), Gemzar(R) and Taxotere(R). MGCD265 is an oral kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. In addition, MethylGene has several preclinical programs: MGCD290 an HDAC inhibitor in combination with azoles for fungal infections; an HDAC program for Huntington's disease; and a sirtuins program for cancer. MethylGene's development and commercialization partners include Pharmion Corporation, Taiho Pharmaceutical and EnVivo Pharmaceuticals. Please visit our website at http://www.methylgene.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements relating to the planned development program for MGCD0103, which express the current beliefs and expectations of management. Such statements are based on current expectations and invol
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
3. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
4. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
5. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
6. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
7. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
8. InterMune Announces Start of Phase 1b Trial of ITMN-191
9. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
10. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Oct. 30, 2014 /CNW/ - Atlantic Canadians will save ... between Canada,s provinces and territories ... President of the Canadian Generic Pharmaceutical Association (CGPA), said ... while speaking at the Atlantic Summit on Healthcare and ... which is being hosted by the Public Policy Forum ...
(Date:10/30/2014)... 30, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology, and medical ... and the United States , ... the Tel Aviv area of ... WuXi,s broad platform of integrated R&D services to local ...
(Date:10/30/2014)... , Oct. 30, 2014   ViaDerma, Inc. ... to bringing new products to market, has recently ... TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic ... that can convert oral medication active ingredients into ... a first aid antibiotic to help prevent skin ...
Breaking Medicine Technology:Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 2Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 3WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3
... K-V Pharmaceutical Company (NYSE:  KVa/KVb) announced today that it ... Administration ("FDA") of the successful completion of an inspection ... first product to market.  Under the Company,s Consent Decree, ... and facilities are expected to be required before K-V ...
... Inc. Promote PurCotton(R) Brand in Shenzhen -- SHENZHEN, China, Sept. 10 /PRNewswire-Asia/ -- ... ... --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
Cached Medicine Technology:K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 2K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 3K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 4K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 5K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 6K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 7K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 8Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 2Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 3Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 4Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 5Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 6Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 7Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 8
(Date:10/31/2014)... In the first study of its kind, Rice University ... circuits that cause cancer cells to become metastatic. The ... allows cancer cells to both migrate and form new ... to new drugs that interfere with the genetic switches ... cells and circulating tumor cells -- two of the ...
(Date:10/31/2014)... Daily Gossip writes in its Xtreme Fat Loss ... fastest fat loss program ever developed. It promises to provide ... There is no wonder after all that this has become ... new nutrition and workout fat loss program was created by ... According to the author of this fat loss system, the ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 With all ... one Midwest optometrist feels they may overlook one critical ... affect areas like concentration, school performance and even behavior. ... too brief to identify progressive vision problems, and to ... Mo., announces a new initiative: The Awesome Eyes Student ...
(Date:10/31/2014)... 2014 (HealthDay News) -- Sleep apnea may make it hard ... parked your car or left your house keys, a small ... apnea showed that this ability -- called spatial memory -- ... sleep, even when other stages of sleep weren,t affected. REM ... typically occur. "We,ve shown for the first time that ...
(Date:10/31/2014)... of four older Americans say that either they or ... treatment, according to the latest issue of The Gerontological ... ( PP&AR ), which goes on to show ... fail to honor patients, end-of-life health care wishes. , ... Issues and Options ," features 12 articles that present ...
Breaking Medicine News(10 mins):Health News:Decoding the emergence of metastatic cancer stem cells 2Health News:Decoding the emergence of metastatic cancer stem cells 3Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Advance directives can benefit patients, families, and health care system 2
... ... Better , ... 2010 -- He,s no guru. And he’s not selling a philosophy, a religion, or telling ... Still the stories surrounding this young Croatian have spawned hundreds of thousands all over Europe ...
... it helps build strength and flexibility, aids relaxation, experts ... is safe for pregnant women, as long as they ... say. , "Women who are expecting can benefit greatly ... be aware of their limitations," orthopaedic surgeon and mom-to-be ...
... ... nasty germs has just become a little easier. If you’re like most of ... spraying everything is sight. Let’s face it -- no one likes germs. ... Arnot Thursday, May 27th at 7:00am (ET/PT), as they air on Lifetime Television. ...
... Highly anticipated Speed ... ... Trek Bicycle , the world leader in bicycle technology and innovation, officially launched its ... the backdrop of the Amgen Tour of California’s Stage 7 Time Trial in Los Angeles. ...
... ... software to Windows dedicated server & Windows VPS (virtual private server) hosting clients at ... customer service software and SmarterStats Web log analytics and SEO software. It is valued ... ...
... ... ... On this edition of The Balancing Act, we are bringing viewers some vitally important information about ... talk about a plan that can help make sure that your family is covered. , ...
Cached Medicine News:Health News:Regular Guy "Braco" Healing Masses in Europe 2Health News:Yoga's Benefits Outweigh Risks for Pregnant Women 2Health News:O2 Media's Hit Morning Show ‘The Balancing Act' Welcomes Dr. Bob Arnot to the Program 2Health News:Trek Introduces Speed Concept Triathlon Bikes 2Health News:Trek Introduces Speed Concept Triathlon Bikes 3Health News:Trek Introduces Speed Concept Triathlon Bikes 4Health News:Dedicate Server and VPS Hosting Provider Company HostRightNow Technologies Partners with SmarterTools Inc. 2Health News:O2 Media's Hit Morning Show ‘The Balancing Act' Welcomes HSA Bank to the Program 2
... Rapid Plasma Reagin ... rapid detection and quantitative ... serum or plasma. Uses ... to detect reagin. Kits ...
Latex agglutination slide test for the qualitative and semi-qualitative detection of antinuclear antibodies to aid in the diagnosis of systemic lupus erthyematosus....
... Rapid Plasma Reagin card ... detection and quantitative determination ... or plasma. Uses carbon ... detect reagin. Kits include ...
Test for the quantitative determination of antideoxyribonuclease-B (ADNase-B) in serum....
Medicine Products: